During the corresponding time, Tonix Pharmaceuticals Holding Corp recorded a revenue increase by 577.88 % year on year, sequentially revenue grew by 96.92 %. While revenue at the Tonix Pharmaceuticals Holding Corp 's corporate clients
Tonix Pharmaceuticals Holding's Comment on Sales, Marketing and Customers
The company holds worldwide commercialization rights to TONMYA, Zembrace SymTouch, and Tosymra, products indicated for the treatment of acute migraine in adults. Zembrace SymTouch and Tosymra were acquired from Upsher-Smith in June 2023. Zembrace SymTouch is the only actively promoted sumatriptan autoinjector brand in the U.S. and is protected by patents until 2036. Tosymra incorporates Intravail® technology and has patent protection until 2031. These products support the company's commercial platform, which includes sales, marketing, market access, distribution, and patient support.
The company also has several product candidates in development targeting conditions such as Major Depressive Disorder, Acute Stress Reaction/Disorder, Lyme Disease prevention, Kidney Transplant Rejection, Cocaine Intoxication, Adolescent Obesity, Prader-Willi Syndrome, Smallpox and Mpox vaccines, viral diseases, neuropathic pain, and gastric and colorectal cancer. TNX-102 SL, approved as TONMYA for fibromyalgia in the U.S., is a proprietary sublingual tablet formulation of cyclobenzaprine. The company holds active Investigational New Drug applications for other indications but is not currently studying TNX-102 SL for PTSD, Acute Anxiety Disorder, Long Covid, or Alcohol Use Disorder. The company owns all global rights to TNX-102 SL without third-party obligations for development or commercialization.
News about Tonix Pharmaceuticals Holding Corp Contracts
Bridging Horizons: Tonix Pharmaceuticals Dual Frontier in Mpox Prevention and Fibromyalgia ReliefIn a significant advancement towards global health security, Tonix Pharmaceuticals has announced a pivotal research collaboration with the Kenya Medical Research Institute (KEMRI). This initiative aims to design, strategize, and obtain regulatory approval for a pioneering Phase I clinical study of TNX-801, a forward-looking vaccine against mpox, in Kenya. Concurrently, the pharmaceutical company is making strides in the treatment of fibromyalgia through its novel formulation, TNX-102 SL, garnering attention at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024).The proposed c...
The pharmaceutical industry is undergoing a paradigm shift due to advancements in technology, particularly in the realms of artificial intelligence (AI) and machine learning (ML). This transformation is garnering attention not only for its potential in drug discovery but also for enhancing the strategic commercialization of pharmaceutical products. Recent developments by Tonix Pharmaceuticals highlight the integration of AI in antiviral drug discovery alongside its sophisticated launch strategy for Tonmya, a new potential treatment for fibromyalgia. This article elaborates on these two pivotal initiatives, underscoring their significance in modern therapeutics and addressing the complexities of drug developm...
Tonix Pharmaceuticals Holding Corp has recently marked a significant milestone by participating in a pivotal Endpoints Panel at the Long COVID Workshop and the RECOVER TLC Workshop. These events were convened by the Foundation for the National Institutes of Health (FNIH) and the National Institute of Allergy and Infectious Diseases (NIAID), reflecting an ongoing commitment to addressing the complexities surrounding Long COVID. The company’s involvement signifies an active role in the broader scientific community seeking to understand and effectively treat individuals suffering from this post-viral syndrome.Long COVID has emerged as a pressing global health concern, affecting millions of individuals with pr...
Tonix Pharmaceuticals Holding Corp has recently presented promising preclinical data for its Mpox vaccine, TNX-801, at the Immunology Symposium at the University of Alberta. This development comes at a time when the company faces significant financial pressures, including a cumulative net loss of $153 million over the past year and a negative return on assets (ROA) of -122.58%. While the long-term potential of TNX-801 in combatting Mpox is noteworthy, the financial standing of Tonix Pharmaceuticals raises questions about the sustainability of their innovations and the strategic direction of the company.The emergence of infectious diseases such as Mpox highlighted the urgent need for effective vaccines. Toni...
In an exciting development that signals hope for both patients and clinicians, Tonix Pharmaceuticals has announced the enrollment of the first patient in its Phase 2 study, named CATALYST, assessing TNX-1300 as a potential treatment for cocaine intoxication. This pivotal moment underscores the company s commitment to addressing the urgent needs of individuals affected by substance use disorders, particularly in emergency settings.The CATALYST study is designed as a single-blind, placebo-controlled, proof-of-concept trial. It aims to evaluate the safety and efficacy of TNX-1300 in patients presenting to emergency departments with acute cocaine intoxication, a condition that poses critical health risks and cha...
Expanding Therapeutic Horizons: Innovations from Tonix Pharmaceuticals in Antibody Development, Migraine Treatment, and Transplant Immunology As the landscape of pharmaceutical science continuously evolves, the pursuit of innovative therapeutic solutions remains at the forefront. Recently, Tonix Pharmaceuticals has unveiled critical advancements that not only enhance their capabilities in generating potential therapeutic interventions but also align with the pressing public health needs, particularly in the realms of infectious disease, migraine management, and transplantation. 1. Advancements in Antibody Development Against SARS-CoV-2 Tonix Pharmaceuticals has announced a significant advancement published i...
Tonix Pharmaceuticals Awarded $34 Million U.S. Department of Defense Contract for Rapid Development of Broad-Spectrum Antiviral ProgramIn a major achievement, Tonix Pharmaceuticals has been granted a defense contract by the U.S. Department of Defense, specifically the Defense Threat Reduction Agency (DTRA), worth up to $34 million. This lucrative award is expected to expedite the advancement of Tonix s groundbreaking broad-spectrum oral antiviral program, TNX-4200, as a cutting-edge medical countermeasure.The global COVID-19 pandemic has revealed the critical need for effective antiviral treatments, not only for future outbreaks but also for combating other infectious diseases. Recognizing this urgency, the ...
Tonix Pharmaceuticals, a renowned pharmaceutical company dedicated to improving the lives of patients suffering from chronic pain conditions, recently presented significant data at the Annual Scientific Meeting of the American Headache Society (AHS). The data showcased a comparison between real-world treatment of migraines and the industry guidelines for non-oral products, exposing a considerable gap. This gap, relative to the AHS guidelines, presents an incredible opportunity for Tonix to increase awareness of its two FDA-approved non-oral treatments for acute migraines.Furthermore, Tonix Pharmaceuticals is preparing to deliver an engaging oral presentation and present two posters at the upcoming American S...
Fibromyalgia is a debilitating condition characterized by chronic pain, fatigue, and cognitive difficulties, commonly referred to as brain fog. The search for an effective treatment has proven challenging, with limited options currently available. However, Tonix Pharmaceuticals, a leading biopharmaceutical company, recently presented promising data at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. Their investigational drug, Tonmya (TNX-102 SL), has shown significant improvement in fibromyalgia symptoms, bringing renewed hope to patients and healthcare professionals alike.Positive Results from the Phase 3 RESILIENT Study:The Phase 3 RESILIENT study of Tonmya included a diverse coh...
Tonix Pharmaceuticals, a leading biopharmaceutical company, recently announced the selection of two contract manufacturing organizations for the launch and commercial manufacture of Tonmya. Tonmya is an innovative first-line, centrally acting non-opioid analgesic that shows great promise in managing fibromyalgia. Supported by the positive results from two Phase 3 studies, this development heralds a potential breakthrough in the treatment of this debilitating condition.Outline of Facts: 1. Tonmya s Potential: Tonmya is being hailed as a potential game-changer in the management of fibromyalgia, a condition characterized by chronic widespread pain and heightened sensitivity to touch. As a non-opioid alternativ...
Tonix Pharmaceuticals Holding’s Comment on Sales, Marketing and Customers
The company holds worldwide commercialization rights to TONMYA, Zembrace SymTouch, and Tosymra, products indicated for the treatment of acute migraine in adults. Zembrace SymTouch and Tosymra were acquired from Upsher-Smith in June 2023. Zembrace SymTouch is the only actively promoted sumatriptan autoinjector brand in the U.S. and is protected by patents until 2036. Tosymra incorporates Intravail® technology and has patent protection until 2031. These products support the company's commercial platform, which includes sales, marketing, market access, distribution, and patient support.
The company also has several product candidates in development targeting conditions such as Major Depressive Disorder, Acute Stress Reaction/Disorder, Lyme Disease prevention, Kidney Transplant Rejection, Cocaine Intoxication, Adolescent Obesity, Prader-Willi Syndrome, Smallpox and Mpox vaccines, viral diseases, neuropathic pain, and gastric and colorectal cancer. TNX-102 SL, approved as TONMYA for fibromyalgia in the U.S., is a proprietary sublingual tablet formulation of cyclobenzaprine. The company holds active Investigational New Drug applications for other indications but is not currently studying TNX-102 SL for PTSD, Acute Anxiety Disorder, Long Covid, or Alcohol Use Disorder. The company owns all global rights to TNX-102 SL without third-party obligations for development or commercialization.
Sources:
Tonix Pharmaceuticals Holding Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Tonix Pharmaceuticals Holding Corp’s corporate clients.
For your research, we’ve provided 9 tables on Tonix Pharmaceuticals Holding Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
108.42 %